ZIM Laboratories receives grant to market Rizatriptan product in Portugal, Europe

  • India Infoline News Service |
  • 05 Jul, 2021 |
  • 9:15 AM
ZIM Laboratories Limited, a pioneer in the Oral Dissolving Film (“ODF”) dosage form technology, has announced that Infarmed has granted marketing authorization for its innovative product, Rizatriptan Orally Dissolving Film in Portugal, Europe to its wholly-owned European subsidiary.

Rizatriptan is widely used for relief from Migraine attacks. Migraine was ranked as the fifth leading cause of years lived with disability (YLD) in Western Europe and the sixth leading cause of YLD in Central and Eastern Europe in the Global Burden of Disease.

The economic burden of migraine is significant. Different European studies have estimated the cost of migraine at €18 billion to €27 billion depending on study setting and design. The majority of all migraine-related costs (77–93%) are indirect costs attributed primarily to work productivity losses.

Migraine is often associated with symptoms such as nausea, vomiting, phonophobia (sensitivity to sound), and photophobia (sensitivity to light) and because of the severity of the symptoms it needs medication that can be given to patient without making these symptoms worse and that also produces a faster onset of action.

Rizatriptan Orally Dissolving Film is a product developed using Thinoral technology which yields instantly wettable, rapidly dissolving, and stable films. The fast dissolving feature provides potentially faster onset of action, and the flexible nature of film dosage form allows for convenience in handling and administration.

As the presently available product in the market is a mouth dissolving tablet which is extremely fragile, Zim’s product offering is likely to provide significant advantage to patients in terms of portability as well as faster action. Rizatriptan orally dissolving film by virtue of its convenience in administration ensures treatment adherence and will help to reduce economic burden. The global market of Rizatriptan is about 200 million USD.

Commenting on the granting of the marketing authorisation, Dr. Anwar Daud, Managing Director of Zim Laboratories Limited said, “The approval of this novel orally dissolving film is further evidence of Zim Lab's determination to become the preferred partner for our clients who are seeking innovative new therapies to treat unmet needs for the patients and physicians.”

On Monday morning trade, Zim Laboratories was currently trading at Rs172.15 apiece down by 0.09% on Sensex.

Invest wise with Expert advice

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
ad IconAd Image

Most Read News

Article Image
  • 14 March, 2022 |
  • 7:03 AM

The US Federal committee's meeting will conclude on March 16, 2022.

Most Shared News

No Record Found